Research Update

RNS Number:0938T
ReGen Therapeutics PLC
10 December 2003


ReGen Therapeutics Plc


10th December 2003


Research & Development Update


Percy Lomax, chairman of ReGen Therapeutics Plc, ("ReGen" or "the Company")
which is developing ColostrininTM, as a treatment for Alzheimer's disease, is
today chairing a briefing to investors and analysts, when he will be updating
them on research and development progress made over the last 12 months.


A clinical trial of ColostrininTM on 106 patients demonstrated statistically
significant efficacy as measured by ADAS cog (a measure of cognitive/memory
function) in treated patients, with no safety concerns. Following completion of
this trial ReGen has, over the last 18 months, been undertaking an extensive
scientific development programme, much of it in collaboration with the
University of Texas Medical Branch (UTMB).


Key areas of activity have focused on developing a greater understanding of the
mode of action of ColostrininTM, which in turn has enabled development of
bio-assays and the identification of animal (in-vivo) models. These are crucial
elements in developing an effective manufacturing process and fully evaluating
the therapeutic potential of ColostrininTM in Alzheimer's and other diseases.
Progress made to date encourages the Company to believe that continuation of
this work will place ReGen in a position to begin the next stage of clinical
development around the end of 2004.


The Company anticipates that such clinical trials will be undertaken in
collaboration with a co-development/commercialisation partner. In this context
ReGen states that it is working with a licensing company to assist with finding
such a partner.


ReGen has also made considerable progress in planning the development
opportunities for ColostrininTM as a nutraceutical, in particular in the United
States.


With regard to the manufacturing of ColostrininTM, it has been confirmed that the
more readily available bovine colostrum (as opposed to ovine), can be used as
the source material, and a contract has recently been agreed and is awaiting
signature with a major US bovine colostrum processor, which will enable
cost-effective access to a manufacturing facility without any major capital
expenditure.


Finally, although preliminary data only is available at the moment a proteomics
screen with ColostrininTM has shown that it has the ability to selectively
modulate the expression of proteins by nerve cells in culture. This confirms
that active principles within ColostrininTM are able to activate cells and direct
the synthesis of proteins. The nature of these proteins is now being
investigated. This work offers the prospect of shedding even more light on the
way ColostrininTM works and identifying new potential disease targets and uses.


Further information:


Andrew Marshall

Marshall Robinson Roe

Tel No: 020 7960 6007






                      This information is provided by RNS
            The company news service from the London Stock Exchange

END
RESFFIFESSDSEDE